Granules India Ltd.

“Granules India is a well-run but structurally average business — vertically integrated in commodity molecules with a real but narrow cost moat, executing a credible Finished Dosages mix-shift, and led by a clean founder with genuine skin in the game. However, at 31x trailing and 23x forward earnings near its 52-week high, the stock is priced for the bull case with no discount for the single most important tail risk: an FDA import alert on its US-facing facilities, which would cause permanent, not cyclical, impairment. Incremental returns on capital are compressing toward WACC, the R&D pipeline offers minimal optionality compared to peers, and historical governance blemishes (promoter pledging) are resolved but not forgotten. This is a hold-what-you-own situation at best; fresh capital belongs in businesses with wider moats, better reinvestment economics, or a genuine margin of safety.”